Increased dynamic binding capacity with smaller particle size and greater porosity than MabSelect medium. MabSelect Xtra uses the same recombinant protein A ligand as MabSelect Oriented coupling of recombinant Protein A to the matrix via an engineered Cterminal cysteine enhances IgG binding capacity. Fewer regulatory concerns due to the total absence of mammalian culture in the ligand production and purification. Prepacked HiTrap columns for process development, screening of purification conditions, and small scale purification of Mabs.
